Vericel Corporation (VCEL): Price and Financial Metrics


Vericel Corporation (VCEL)

Today's Latest Price: $23.45 USD

0.23 (-0.97%)

Updated Nov 23 4:00pm

Add VCEL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

VCEL Stock Summary

  • With a price/earnings ratio of 7,418.99, Vericel Corp P/E ratio is greater than that of about 99.75% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for Vericel Corp is higher than 96.33% of stocks in our set with a positive cash flow.
  • With a price/sales ratio of 9.09, Vericel Corp has a higher such ratio than 84.41% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Vericel Corp, a group of peers worth examining would be POST, CNMD, QADB, WPRT, and ESRT.
  • Visit VCEL's SEC page to see the company's official filings. To visit the company's web site, go to vcel.com.

VCEL Stock Price Chart Interactive Chart >

Price chart for VCEL

VCEL Price/Volume Stats

Current price $23.45 52-week high $26.22
Prev. close $23.68 52-week low $6.78
Day low $23.26 Volume 391,753
Day high $24.18 Avg. volume 634,315
50-day MA $20.95 Dividend yield N/A
200-day MA $16.05 Market Cap 1.07B

Vericel Corporation (VCEL) Company Bio


Vericel Corporation focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company was founded in 1989 and is based in Cambridge, Massachusetts.

VCEL Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$23.45$0 -100%

We started the process of determining a valid price forecast for Vericel Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Vericel Corp ranked in the 0th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Vericel Corp, consider:

  • Its compound free cash flow growth rate, as measured over the past 0.25 years, is -0.7% -- higher than only 1.07% of stocks in our DCF forecasting set.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-100%
1%-100%
2%-100%
3%-100%
4%-100%
5%-100%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as VCEL, try AGHC, ALC, AMRN, ATRS, and MOR.


VCEL Latest News Stream


Event/Time News Detail
Loading, please wait...

VCEL Latest Social Stream


Loading social stream, please wait...

View Full VCEL Social Stream

Latest VCEL News From Around the Web

Below are the latest news stories about Vericel Corp that investors may wish to consider to help them evaluate VCEL as an investment opportunity.

Vericel (VCEL) Investor Presentation - Slideshow

The following slide deck was published by Vericel Corporation in conjunction with this event....

SA Transcripts on Seeking Alpha | September 18, 2020

MediWound: An Underfollowed Opportunity At A Discount

MediWound (MDWD) has popped up on my scanner several times over the past couple of years following some potent company press releases and catalysts. Admittedly, I would take a look at the headline and then check the ticker only to see a big move followed by a fade, so I...

Biologics on Seeking Alpha | September 8, 2020

World Cell & Gene Therapy Markets, 2025 - Leading Players are Gilead Sciences, Spark Therapeutics, Novartis, Organogenesis, Amgen, Osiris Therapeutics, Dendreon, and Vericel - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cell & Gene Therapy Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included The study considers the present scenario of the cell and gene therapy market and its market dynamics for the period 2019-2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and suppl

Business Wire | August 6, 2020

Vericel (VCEL) Q2 2020 Earnings Call Transcript | The Motley Fool

VCEL earnings call for the period ending June 30, 2020.

The Motley Fool | August 6, 2020

Vericel Reports Second Quarter 2020 Financial Results

Product Revenues of $20.0 Million Reported for the Second Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE…

GlobeNewswire | August 5, 2020

Read More 'VCEL' Stories Here

VCEL Price Returns

1-mo 13.01%
3-mo 39.58%
6-mo 63.87%
1-year 26.42%
3-year 451.76%
5-year 946.88%
YTD 34.77%
2019 0.00%
2018 219.27%
2017 81.67%
2016 16.28%
2015 -15.13%

Continue Researching VCEL

Here are a few links from around the web to help you further your research on Vericel Corp's stock as an investment opportunity:

Vericel Corp (VCEL) Stock Price | Nasdaq
Vericel Corp (VCEL) Stock Quote, History and News - Yahoo Finance
Vericel Corp (VCEL) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0477 seconds.